Rajkot News Today

Hyperkalemia Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

 Breaking News
  • No posts were found

Hyperkalemia Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

January 21
19:00 2021
Hyperkalemia Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Hyperkalemia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hyperkalemia, historical and forecasted epidemiology as well as the Hyperkalemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hyperkalemia is defined as the high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death. Risk factors for hyperkalemia include several conditions such as chronic kidney disease, diabetes, congestive heart failure and certain medications that disrupt the potassium balance. Also, males are found to suffer more than females with Hyperkalemia.

Get FREE sample copy at: 
https://www.delveinsight.com/sample-request/hyperkalemia-market

The Hyperkalemia market report also covers emerging drugs, current treatment practices, Hyperkalemia market share of the individual therapies, current and forecasted Hyperkalemia Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Hyperkalemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

Hyperkalemia Market

 

Hyperkalemia Market Key Facts
According to the National Kidney Foundation, prevalence and incidence of Hyperkalemia have been estimated to be 2-3% in the general population and about 1-10% among hospitalized patients. People with chronic kidney disease, heart failure, diabetes mellitus, and those taking blood pressure medicines (RAASi) have an estimated 2–3 times higher risk for hyperkalemia. More than half of pre-dialysis CKD patients are at risk of developing Hyperkalemia.

In a study conducted by Betts et al. (2018), it was estimated that the annual prevalence of hyperkalemia was 1.57% in 2014, with higher rates observed in patients with chronic kidney disease (CKD), heart failure, diabetes, and hypertension. Among patients with CKD and/or heart failure, the 2014 annual prevalence was 6.35%.

Key Benefits of Hyperkalemia Market Report

  • Hyperkalemia market report provides an in-depth analysis of Hyperkalemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Hyperkalemia market report will help in developing business strategies by understanding the Hyperkalemia Market trends & developments, key players and future market competition that will shape and drive the Hyperkalemia market in the upcoming years.

  • The Hyperkalemia market report covers Hyperkalemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Hyperkalemia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Hyperkalemia Market
The Hyperkalemia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hyperkalemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Hyperkalemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Hyperkalemia Epidemiology
The Hyperkalemia epidemiology section covers insights about historical and current Hyperkalemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Hyperkalemia Drugs Uptake and Key Market Players
The Hyperkalemia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperkalemia market or expected to get launched in the market during the study period. The analysis covers Hyperkalemia market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Some of the key companies in the Hyperkalemia market include:
AstraZeneca
Ardelyx
Vifor Pharma
Zeria Pharmaceutical
And others.

Hyperkalemia Therapies Covered:
Veltassa
Lokelma
RDX013
And many others.

Table of Content

1. Key Insights

2. Executive Summary 

3. Hyperkalemia Competitive Intelligence Analysis

4. Hyperkalemia Market Overview at a Glance

5. Hyperkalemia Disease Background and Overview

6. Hyperkalemia Patient Journey

7. Hyperkalemia Epidemiology and Patient Population

8. Hyperkalemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperkalemia Unmet Needs

10. Key Endpoints of Hyperkalemia Treatment

11. Hyperkalemia Marketed Products

12. Hyperkalemia Emerging Therapies

13. Hyperkalemia Seven Major Market Analysis

14. Attribute Analysis

15. Hyperkalemia Market Outlook (7 major markets)

16. Hyperkalemia Access and Reimbursement Overview

17. KOL Views on the Hyperkalemia Market.

18. Hyperkalemia Market Drivers

19. Hyperkalemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports
Hyperkalemia Epidemiology Forecast 
DelveInsight’s Hyperkalemia – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hyperkalemia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hyperkalemia Pipeline Insights
Hyperkalemia Pipeline Insight, 2020 report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Hyperkalemia market.

 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles